Literature DB >> 31662523

Axillary Dissection vs. no Axillary Dissection in Breast Cancer Patients With Positive Sentinel Lymph Node: A Single Institution Experience.

Riccardo Arisio1, Fulvio Borella2, Mauro Porpiglia2,3, Antonio Durando3,4, Roberto Bellino3,4, Maria Grazia Bau3,5, Corrado DE Sanctis3,5, Saverio Danese3,6, Chiara Benedetto2, Dionyssios Katsaros7,3.   

Abstract

BACKGROUND/AIM: Axillary surgery of breast cancer patients is undergoing a paradigm shift, as axillary lymph node dissection's (ALND) usefulness is being questioned in the treatment of patients with tumor-positive sentinel lymph node biopsy (SLNB). The aim of this study was to investigate the overall survival (OS) and relapse-free survival (RFS) of patients with positive SLNB treated with ALND or not. PATIENTS AND METHODS: We investigated 617 consecutive patients with cN0 operable breast cancer with positive SLNB undergoing mastectomy or conservative surgery. A total of 406 patients underwent ALND and 211 were managed expectantly.
RESULTS: No significant difference in OS and RFS was found between the two groups. The incidence of loco-regional recurrence in the SLNB-only group and the ALND group was low and not significant.
CONCLUSION: The type of breast cancer surgery and the omission of ALND does not improve OS or RSF rate in cases with metastatic SLN. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Axillary surgery; breast cancer; breast conservative surgery; local recurrence; mastectomy; sentinel lymph node biopsy

Mesh:

Year:  2019        PMID: 31662523      PMCID: PMC6899081          DOI: 10.21873/invivo.11689

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  26 in total

1.  Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection.

Authors:  Takamaru Ashikaga; David N Krag; Stephanie R Land; Thomas B Julian; Stewart J Anderson; Ann M Brown; Joan M Skelly; Seth P Harlow; Donald L Weaver; Eleftherios P Mamounas; Joseph P Costantino; Norman Wolmark
Journal:  J Surg Oncol       Date:  2010-08-01       Impact factor: 3.454

2.  Outcomes with and without axillary node dissection for node-positive lumpectomy and mastectomy patients.

Authors:  Rachael Snow; Chantal Reyna; Caroline Johns; M Catherine Lee; Weihong Sun; William J Fulp; John V Kiluk; Christine Laronga
Journal:  Am J Surg       Date:  2015-06-26       Impact factor: 2.565

3.  Axillary Lymphadenectomy in Sentinel Lymph Node-Positive Breast Cancer.

Authors:  Liling Zhu; Kai Chen; Lisa K Jacobs; Rebecca Aft
Journal:  Ann Surg Oncol       Date:  2017-03-31       Impact factor: 5.344

4.  Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes.

Authors:  U Veronesi; G Paganelli; V Galimberti; G Viale; S Zurrida; M Bedoni; A Costa; C de Cicco; J G Geraghty; A Luini; V Sacchini; P Veronesi
Journal:  Lancet       Date:  1997-06-28       Impact factor: 79.321

5.  Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery: a prospective Swiss multicenter study on 659 patients.

Authors:  Igor Langer; Ulrich Guller; Gilles Berclaz; Ossi R Koechli; Gabriel Schaer; Mathias K Fehr; Thomas Hess; Daniel Oertli; Lucio Bronz; Beate Schnarwyler; Edward Wight; Urs Uehlinger; Eduard Infanger; Daniel Burger; Markus Zuber
Journal:  Ann Surg       Date:  2007-03       Impact factor: 12.969

6.  Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.

Authors:  Armando E Giuliano; Kelly K Hunt; Karla V Ballman; Peter D Beitsch; Pat W Whitworth; Peter W Blumencranz; A Marilyn Leitch; Sukamal Saha; Linda M McCall; Monica Morrow
Journal:  JAMA       Date:  2011-02-09       Impact factor: 56.272

7.  Outcomes of Sentinel Lymph Node-Positive Breast Cancer Patients Treated with Mastectomy Without Axillary Therapy.

Authors:  Elizabeth FitzSullivan; Roland L Bassett; Henry M Kuerer; Elizabeth A Mittendorf; Min Yi; Kelly K Hunt; Gildy V Babiera; Abigail S Caudle; Dalliah M Black; Isabelle Bedrosian; Chantal Reyna; Mediget Teshome; Funda Meric-Bernstam; Rosa Hwang
Journal:  Ann Surg Oncol       Date:  2016-10-03       Impact factor: 5.344

8.  Is axillary lymph node dissection necessary after sentinel lymph node biopsy in patients with mastectomy and pathological N1 breast cancer?

Authors:  Yun Fu; Debra Chung; Minh-An Cao; Sophia Apple; Helena Chang
Journal:  Ann Surg Oncol       Date:  2014-08-01       Impact factor: 5.344

9.  Impact of the american college of surgeons oncology group Z0011 criteria applied to a contemporary patient population.

Authors:  Min Yi; Henry M Kuerer; Elizabeth A Mittendorf; Rosa F Hwang; Abigail S Caudle; Isabelle Bedrosian; Funda Meric-Bernstam; Jamie L Wagner; Kelly K Hunt
Journal:  J Am Coll Surg       Date:  2012-11-02       Impact factor: 6.113

10.  Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial.

Authors:  Armando E Giuliano; Karla Ballman; Linda McCall; Peter Beitsch; Pat W Whitworth; Peter Blumencranz; A Marilyn Leitch; Sukamal Saha; Monica Morrow; Kelly K Hunt
Journal:  Ann Surg       Date:  2016-09       Impact factor: 12.969

View more
  2 in total

1.  Thematic trends and knowledge structure map of sentinel lymph node biopsy for breast cancer: a bibliometric analysis from 2010 to 2019.

Authors:  Yujie Huo; Ting Fan; Si Chen; Qiannan Liu; Yue Fang; Fan Yao
Journal:  Transl Cancer Res       Date:  2022-09       Impact factor: 0.496

2.  Effect of non-sentinel metastasis on adjuvant treatment decisions and survival in Z0011 eligible non-screened detected breast cancer population.

Authors:  Sanjit Kumar Agrawal; Vishal Kewlani; Noopur Priya; Abhishek Sharma; Joydeep Ghosh; Sanjoy Chatterjee; Rosina Ahmed
Journal:  Ecancermedicalscience       Date:  2021-11-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.